Otsuka And Lundbeck Announce U.S. FDA Approval Of Supplemental New Drug Application For Rexulti® (Brexpiprazole) For The Treatment Of Agitation Associated With Dementia Due To Alzheimer’s Disease
11/05/2023 03:48
May 11 (Reuters) - Otsuka Holdings Co Ltd 4578.T :
* OTSUKA HOLDINGS CO LTD - OTSUKA AND LUNDBECK ANNOUNCE U.S.
FDA
APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR REXULTI®
(BREXPIPRAZOLE) FOR THE TREATMENT OF AGITATION ASSOCIATED WITH
DEMENTIA DUE TO ALZHEIMER’S DISEASE
Source text for Eikon: ID:nTSqk8a098
Further company coverage: 4578.T
(Reporting by Eimi Yamamitsu)
((Eimi.Yamamitsu@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug